1. Stocks
    2. /
  2. CSL Ltd (ASX: CSL)
    3. /

CSL Ltd (ASX: CSL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

CSL Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $132.82 billion
P/E Ratio 35.68
Dividend Yield 1.39%
Shares Outstanding 484.21 million
Earnings per share 5.450
Dividend per share 3.97
Year To Date Return 6.20%
Earnings Yield 2.80%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • CSL Ltd (ASX: CSL)
    Latest News

    sad party goer sitting alone after celebration
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a rough session for ASX investors this hump day...

    Read more »

    Person holding Australian dollar notes, symbolising dividends.
    Broker Notes

    The best Australian shares to buy with $7,000 right now

    | James Mickleboro

    Analysts think these shares could give you a good return on investment.

    Read more »

    a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
    Healthcare Shares

    Is CSL the best ASX 100 share to buy now?

    | James Mickleboro

    Bell Potter has good things to say about this blue chip star.

    Read more »

    Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
    Healthcare Shares

    Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

    | Zach Bristow

    Brokers are still bullish.

    Read more »

    Mini house on a laptop.
    Dividend Investing

    Do ASX 200 dividend shares out-earn Aussie property?

    | Bronwyn Allen

    We compare the forecast FY25 dividend yields of the top 10 ASX 200 companies to rental property yields.

    Read more »

    A smiling woman with a handful of $100 notes, indicating strong dividend payments
    How to invest

    How to realistically turn a $7,000 ASX share portfolio into $75,000 by 2030

    | James Mickleboro

    The Australian share market is a great place to grow your wealth. Over the years, countless Aussies have constructed ASX…

    Read more »

    A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
    Blue Chip Shares

    2 of the highest-quality blue chip ASX 200 stocks money can buy

    | James Mickleboro

    Analysts think these blue chips are top buys for investors right now. But why?

    Read more »

    a young farmer stands back and admires his work in arranging bales of hay to form a house shape with two bales balancing against each other to form a roof, perched on bales tipped on their side in an abstract house shape on a freshly harvested paddock.
    Best Shares

    Top ASX shares to buy in November with the market near all-time highs

    | Motley Fool Staff

    Our writers are still finding value in a record-breaking Australian share market.

    Read more »

    Shot of a scientist using a computer while conducting research in a laboratory.
    Healthcare Shares

    Are CSL shares a buy after the biotech's FY25 forecasts?

    | Zach Bristow

    Brokers continue to weigh in.

    Read more »

    Smiling man working on his laptop.
    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    | James Mickleboro

    Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

    Read more »

    Happy young couple saving money in piggy bank.
    How to invest

    4 steps to becoming rich with ASX stocks

    | James Mickleboro

    These are the steps I would take to grow my wealth materially.

    Read more »

    Rising green bar graph with an arrow and a world map, symbolising a rising share price.
    Share Market News

    ASX 200 racing higher on Friday as US Fed slashes interest rates again

    | Bernd Struben

    The ASX 200 is enjoying a strong run amid lower US interest rates.

    Read more »

    Frequently Asked Questions

    CSL was listed on the ASX in June 1994.

    CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.

    Since 2021 CSL has paid an unfranked interim dividend in April and a 10% franked final dividend in September/October.

    CSL has a dividend reinvestment plan, however, it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.

    CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks, the adjusted entry price is equivalent to around 76 cents. 

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    09 Sep 2024 $2.1746 0.00% Final 02 Oct 2024
    11 Mar 2024 $1.7989 0.00% Interim 03 Apr 2024
    11 Sep 2023 $2.0078 6.42% Final 04 Oct 2023
    09 Mar 2023 $1.6215 0.00% Interim 05 Apr 2023
    06 Sep 2022 $1.7583 10.00% Final 05 Oct 2022
    07 Mar 2022 $1.4229 0.00% Interim 06 Apr 2022
    02 Sep 2021 $1.5897 10.00% Final 30 Sep 2021
    04 Mar 2021 $1.3491 0.00% Interim 01 Apr 2021
    10 Sep 2020 $1.4696 0.00% Final 09 Oct 2020
    11 Mar 2020 $1.4713 0.00% Interim 09 Apr 2020
    10 Sep 2019 $1.4545 0.00% Final 11 Oct 2019
    13 Mar 2019 $1.2032 0.00% Interim 12 Apr 2019
    11 Sep 2018 $1.2782 0.00% Final 12 Oct 2018
    14 Mar 2018 $1.0050 0.00% Interim 13 Apr 2018
    12 Sep 2017 $0.0000 0.00% Final 13 Oct 2017
    15 Mar 2017 $0.8378 0.00% Interim 13 Apr 2017
    13 Sep 2016 $0.8867 0.00% Final 07 Oct 2016
    23 Mar 2016 $0.8147 0.00% Interim 15 Apr 2016
    07 Sep 2015 $0.8999 0.00% Final 02 Oct 2015
    16 Mar 2015 $0.7439 0.00% Interim 10 Apr 2015
    08 Sep 2014 $0.6485 0.00% Final 03 Oct 2014
    05 Mar 2014 $0.5888 0.00% Interim 04 Apr 2014
    09 Sep 2013 $0.5698 0.00% Final 04 Oct 2013
    05 Mar 2013 $0.3406 0.00% Interim 05 Apr 2013
    17 Sep 2012 $0.3290 0.00% Final 12 Oct 2012
    14 Mar 2012 $0.2520 0.00% Interim 13 Apr 2012
    19 Sep 2011 $0.3210 6.23% Final 14 Oct 2011
    08 Mar 2011 $0.2450 0.00% Interim 08 Apr 2011
    13 Sep 2010 $0.3308 15.96% Final 08 Oct 2010
    09 Mar 2010 $0.2450 0.00% Interim 09 Apr 2010
    14 Sep 2009 $0.2800 0.00% Final 09 Oct 2009
    17 Sep 2007 $0.4675 58.82% Final 12 Oct 2007
    14 Mar 2006 $0.1960 0.00% Interim 13 Apr 2006
    30 Aug 2005 $0.0753 23.64% Special 10 Oct 2005
    30 Aug 2005 $0.3000 100.00% Final 10 Oct 2005
    29 Mar 2004 $0.1200 100.00% Interim 13 Apr 2004

    CSL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About CSL Ltd

    CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.

    CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.

    CSL’s operational businesses include CSL Behring, CSL Seqirus and CSL Vifor. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).

    The company operates in over 40 countries, predominantly Australia, the United States, Germany, the United Kingdom, and Switzerland.

     

    CSL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Nov 2024 $271.36 $-1.09 -0.40% 1,121,461 $272.45 $275.19 $271.02
    18 Nov 2024 $272.45 $-4.56 -1.65% 890,824 $271.21 $273.30 $270.09
    15 Nov 2024 $277.01 $-7.04 -2.48% 921,020 $280.67 $281.07 $275.01
    14 Nov 2024 $284.05 $-1.49 -0.52% 423,442 $287.55 $287.60 $283.86
    13 Nov 2024 $285.54 $-1.12 -0.39% 392,254 $285.50 $285.86 $282.18
    12 Nov 2024 $286.66 $-0.66 -0.23% 422,699 $287.45 $289.05 $284.54
    11 Nov 2024 $287.32 $2.03 0.71% 518,725 $285.40 $287.70 $285.01
    08 Nov 2024 $285.29 $1.90 0.67% 491,784 $286.24 $286.95 $283.70
    07 Nov 2024 $283.39 $-2.34 -0.82% 472,108 $286.25 $287.25 $281.40
    06 Nov 2024 $285.73 $1.74 0.61% 280,971 $286.36 $287.19 $283.86
    05 Nov 2024 $283.99 $-2.35 -0.82% 346,546 $286.92 $288.00 $283.67
    04 Nov 2024 $286.34 $4.72 1.68% 354,361 $284.00 $287.00 $283.05
    01 Nov 2024 $281.62 $-5.33 -1.86% 620,325 $284.41 $285.00 $281.62
    31 Oct 2024 $286.95 $-0.51 -0.18% 651,806 $289.59 $289.59 $286.05
    30 Oct 2024 $287.46 $-5.21 -1.78% 559,123 $292.00 $292.49 $287.46
    29 Oct 2024 $292.67 $0.67 0.23% 600,035 $291.00 $292.67 $289.64
    28 Oct 2024 $292.00 $-1.69 -0.58% 374,484 $292.05 $294.47 $290.89
    25 Oct 2024 $293.69 $0.12 0.04% 418,678 $294.00 $295.19 $292.26
    24 Oct 2024 $293.57 $2.31 0.79% 415,514 $292.65 $296.03 $291.26
    23 Oct 2024 $291.26 $-2.87 -0.98% 510,871 $294.86 $295.54 $291.02
    22 Oct 2024 $294.13 $-8.90 -2.94% 725,885 $301.00 $302.45 $293.50

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 Oct 2024 Paul McKenzie Sell 4,000 $1,148,600
    On-market trade.
    30 Oct 2024 Paul McKenzie Issued 38,065 $10,942,164
    Issue of securities. 103,522 Performance Share Units
    03 Sep 2024 Paul McKenzie Sell 3,779 $1,149,997
    On-market trade.
    03 Sep 2024 Paul McKenzie Expiry 10,742 $3,287,374
    As advised by the company. Lapsed, 73,732 Rights
    03 Sep 2024 Paul McKenzie Buy 8,275 $2,532,398
    Conversion of securities.
    03 Sep 2024 Paul McKenzie Exercise 8,275 $2,532,398
    Conversion of securities. 65,457 Rights
    21 Aug 2024 Carolyn Hewson Issued 352 $107,036
    Director remuneration. vwap, 352 rights
    21 Aug 2024 Alison Watkins Issued 308 $93,656
    Director remuneration. VWAP, 308 Rights
    21 Aug 2024 Brian McNamee Issued 625 $190,050
    Director remuneration. vwap, 625 Rights
    21 Aug 2024 Robert Cuthbertson Issued 264 $80,277
    Director remuneration. 264 Rights, vwap
    21 Aug 2024 Duncan Maskell Issued 220 $66,897
    Director remuneration. vwap, 220 rights
    21 Aug 2024 Marie McDonald Issued 176 $53,518
    Director remuneration. 176 Rights, vwap
    21 Aug 2024 Samantha (Sam) Lewis Issued 220 $66,897
    Director remuneration. vwap, 220 Rights
    21 Aug 2024 Megan Clark Issued 264 $80,277
    Director remuneration. vwap, 264 Rights
    16 Aug 2024 Carolyn Hewson Buy 193 $58,930
    Conversion of securities.
    16 Aug 2024 Carolyn Hewson Exercise 193 $58,930
    Conversion of securities.
    16 Aug 2024 Alison Watkins Exercise 169 $51,602
    Conversion of securities.
    16 Aug 2024 Alison Watkins Buy 169 $51,602
    Conversion of securities.
    16 Aug 2024 Brian McNamee Buy 343 $104,731
    Conversion of securities.
    16 Aug 2024 Brian McNamee Exercise 343 $104,731
    Conversion of securities.
    16 Aug 2024 Robert Cuthbertson Exercise 145 $44,274
    Conversion of securities.
    16 Aug 2024 Robert Cuthbertson Buy 145 $44,274
    Conversion of securities.
    16 Aug 2024 Duncan Maskell Exercise 338 $103,204
    Conversion of securities.
    16 Aug 2024 Duncan Maskell Buy 338 $103,204
    Conversion of securities.
    16 Aug 2024 Marie McDonald Exercise 145 $44,274
    Conversion of securities.
    16 Aug 2024 Marie McDonald Buy 145 $44,274
    Conversion of securities.
    16 Aug 2024 Samantha (Sam) Lewis Exercise 114 $34,808
    Conversion of securities.
    16 Aug 2024 Samantha (Sam) Lewis Buy 114 $34,808
    Conversion of securities.
    16 Aug 2024 Megan Clark Buy 145 $44,274
    Conversion of securities.
    16 Aug 2024 Megan Clark Exercise 145 $44,274
    Conversion of securities.
    21 Feb 2024 Samantha (Sam) Lewis Issued 114 $32,190
    Director remuneration. VWAP
    16 Feb 2024 Carolyn Hewson Exercise 193 $54,812
    Conversion of securities. 193 Rights
    16 Feb 2024 Carolyn Hewson Buy 193 $54,812
    Conversion of securities.
    16 Feb 2024 Alison Watkins Buy 169 $47,996
    Conversion of securities.
    16 Feb 2024 Alison Watkins Exercise 169 $47,996
    Conversion of securities. 169 Rights
    16 Feb 2024 Brian McNamee Exercise 343 $97,412
    Conversion of securities. 343 Rights
    16 Feb 2024 Brian McNamee Buy 343 $97,412
    Conversion of securities.
    16 Feb 2024 Robert Cuthbertson Buy 145 $41,180
    Conversion of securities.
    16 Feb 2024 Robert Cuthbertson Exercise 145 $41,180
    Conversion of securities. 145 Rights
    16 Feb 2024 Duncan Maskell Exercise 339 $96,276
    Conversion of securities. 338 Rights
    16 Feb 2024 Duncan Maskell Buy 339 $96,276
    Conversion of securities.
    16 Feb 2024 Marie McDonald Buy 145 $41,180
    Conversion of securities.
    16 Feb 2024 Marie McDonald Exercise 145 $41,180
    Conversion of securities. 145 Right
    16 Feb 2024 Megan Clark Exercise 145 $41,180
    Conversion of securities. 145 Rights
    16 Feb 2024 Megan Clark Buy 145 $41,180
    Conversion of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Carolyn Judith Hewson Non-Executive Director Dec 2019
    Ms Hewson is a former investment banker with over 35 years of experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has financial markets, risk management and investment management expertise. She has non-executive experience in several sectors bringing experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture, and the changing external environment. She is Chair of the Corporate Governance Committee, Member of the Risk Management Committee and Human Resources Committee.
    Ms Alison Mary Watkins Non-Executive Director Aug 2021
    Ms Watkins brings experience to the Board through the executive and non executive roles she has held across industries, including manufacturing, agriculture, consumer goods, retail and financial services. She is Chair of Risk Management Committee and Member of the Human Resources Committee.
    Dr Brian Anthony McNamee Non-Executive DirectorNon-Executive Chairman Jan 1990
    Dr McNamee has executive experience in the biopharmaceutical industry, with a focus on strategy and creating shareholder value. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued several private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. He is Member of the Innovation and Development Committee and Corporate Governance.
    Dr Robert Andrew Cuthbertson Non-Executive Director Oct 2018
    Dr Cuthbertson has over 35 years of experience in medical research and biotech development with biopharmaceutical companies and medical organisations. He also has non-executive director experience. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is Chair of the Innovation and Development Committee and Member of the Corporate Governance Committee.
    Ms Marie Elizabeth McDonald Non-Executive Director Aug 2013
    Ms McDonald has executive and non-executive experience in several sectors including law, medical research, manufacturing, and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years of experience in the legal sector. She was previously a Partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She is member of the Risk Management Committee and Human Resources Committee.
    Ms Samantha (Sam) Louise Lewis Non-Executive Director Jan 2024
    Ms Lewis Ms Lewis is a non-executive director serving on boards of ASX 100 companies since 2014. Ms Lewis has experience in accounting, finance, auditing, risk management, corporate governance, capital markets and due diligence. Prior to becoming a Non-executive Director, Ms Lewis spent 24 years with Deloitte, including 14 years as a Partner. In that role, she acted as lead auditor of several Australian listed entities and provided accounting and transactional advisory services including due diligence, IPOs, and debt/equity raisings. Ms Lewis has experience working with companies in the manufacturing, retail, and industrial sectors. She is member of the Risk Management Committee.
    Dr Megan Elizabeth Clark Non-Executive Director Feb 2016
    Dr Clark has executive and non-executive experience across a range of sectors, including scientific research, health, investment banking and financial services, education, and mining. Through her roles, Dr Clark brings a strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. In 2014, Dr Clark was made a Companion of the Order of Australia for eminent service to scientific research and development. He is Chair of the Human Resources Committee, and Member of the Corporate Governance and Innovation and Development Committee.
    Dr Paul McKenzie Chief Operating OfficerExecutive DirectorChief Executive OfficerManaging Director Dec 2022
    Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing organisations through growth and transformation. He changed CSL's global end to end operations, advanced CSL Seqirus differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels. Prior to joining CSL, Dr McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb, and Merck. He is also Member of the Innovation and Development Committee.
    Ms Elaine Sorg Non-Executive Director Sep 2024
    Ms Sorg has more than 35 years experience as a senior executive with pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVies US commercial operations. She is currently on the Deans Advisory Council at Purdue University School of Pharmacy and Pharmaceutical Science, and is a Senior Advisor at the Boston Consulting Group, where she advises global health care clients on business-critical strategies and decisions.
    Ms Fiona Mead Company SecretaryHead of Group Governance Jun 2018
    -
    Kate Priestman Chief Corporate & External Affairs Officer
    -
    Joy Linton Chief Financial Officer
    -
    Roanne Parry Chief Human Resources Officer
    -
    Fiona Mead Company SecretaryHead of Group Governance
    -
    Ken Lim Executive Vice President and Chief Strategy Officer
    -
    Mark Hill Executive Vice President Chief Digital Information Officer
    -
    Andy Schmeltz Executive Vice President CSL Behring
    -
    Bill Mezzanotte Executive Vice President Head of Research & Development
    -
    Greg Boss Executive Vice President Legal and CSL Group General Counsel
    -
    Dave Ross Senior Vice President and General Manager CSL Seqirus
    -
    Herve Gisserot Senior Vice President and General Manager CSL Vifor
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 162,829,983 33.69%
    P Morgan Nominees Australia Pty Limited 86,779,316 17.96%
    Citicorp Nominees Pty Limited 46,160,603 9.55%
    Bnp Paribas Nominees Pty Ltd <Agency Lending A/C> 11,290,713 2.34%
    National Nominees Limited 8,358,823 1.73%
    BNP Paribas Noms Pty Ltd 7,126,947 1.47%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 5,206,440 1.08%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,491,236 0.72%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 2,862,019 0.59%
    Netwealth Investments Limited <Wrap Services A/C> 2,822,828 0.58%
    Australian Foundation Investment Company Limited 2,239,500 0.46%
    Solium Nominees (Australia) Pty Ltd <Allocated A/C> 1,682,180 0.35%
    Custodial Services Limited <Beneficiaries Holding A/C> 1,611,222 0.33%
    Argo Investments Limited 1,341,509 0.28%
    Mutual Trust Pty Ltd 1,051,510 0.22%
    BNP Paribas Noms (Nz) Ltd 1,024,918 0.22%
    Solium Nominees (Australia) Pty Ltd <Vsa A/C> 796,200 0.16%
    D W S Nominees Pty Ltd 793,208 0.17%
    IOOF Investment Services Limited <Ioof Idps A/C> 687,223 0.14%
    Ioof Investment Services Limited <Ips Superfund A/C> 669,103 0.14%

    Profile

    since

    Note